We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Anika Therapeutics (ANIK - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Anika Therapeutics is a member of the Medical sector. This group includes 915 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Anika Therapeutics is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ANIK's full-year earnings has moved 118.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ANIK has returned 110.5% so far this year. In comparison, Medical companies have returned an average of 2.4%. This shows that Anika Therapeutics is outperforming its peers so far this year.
Concentra Group (CON - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 75.9%.
The consensus estimate for Concentra Group's current year EPS has increased 7.9% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Anika Therapeutics is a member of the Medical - Biomedical and Genetics industry, which includes 437 individual companies and currently sits at #172 in the Zacks Industry Rank. On average, stocks in this group have gained 6.9% this year, meaning that ANIK is performing better in terms of year-to-date returns.
On the other hand, Concentra Group belongs to the Medical Services industry. This 72-stock industry is currently ranked #95. The industry has moved +3.8% year to date.
Investors interested in the Medical sector may want to keep a close eye on Anika Therapeutics and Concentra Group as they attempt to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Anika Therapeutics (ANIK - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Anika Therapeutics is a member of the Medical sector. This group includes 915 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Anika Therapeutics is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ANIK's full-year earnings has moved 118.9% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ANIK has returned 110.5% so far this year. In comparison, Medical companies have returned an average of 2.4%. This shows that Anika Therapeutics is outperforming its peers so far this year.
Concentra Group (CON - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 75.9%.
The consensus estimate for Concentra Group's current year EPS has increased 7.9% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Anika Therapeutics is a member of the Medical - Biomedical and Genetics industry, which includes 437 individual companies and currently sits at #172 in the Zacks Industry Rank. On average, stocks in this group have gained 6.9% this year, meaning that ANIK is performing better in terms of year-to-date returns.
On the other hand, Concentra Group belongs to the Medical Services industry. This 72-stock industry is currently ranked #95. The industry has moved +3.8% year to date.
Investors interested in the Medical sector may want to keep a close eye on Anika Therapeutics and Concentra Group as they attempt to continue their solid performance.